HETEROCYCLIC DERIVATIVES THAT ARE USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
申请人:Schmidt Fanny
公开号:US20110118270A1
公开(公告)日:2011-05-19
The present invention relates to compounds of Formula (I) below, to their pharmaceutically acceptable salts and to their isomers or mixtures of isomers: HetAr—X—CHR
1
R
2
(I) in which: -HetAr represents a group chosen from: —X represents a linear, saturated or unsaturated, hydrocarbon-based chain comprising from 8 to 22 carbon atoms, optionally interrupted by an —NH— or —NH—CO— group, —R
1
represents a hydrogen atom or an —OH, —O(C
1
-C
6
)alkyl, —OCO((C
1
-C
6
)alkyl), —OSO
2
((C
1
-C
6
)alkyl) or —OSO
3
H group, and —R
2
represents a hydrogen atom or a (C
2
-C
6
)alkynyl, (C
2
-C
6
)alkenyl or (C
3
-C
6
)cycloalkyl group. The present invention also relates to a process for preparing the compounds of Formula (I), and also to the use thereof, especially in the treatment of neurodegenerative diseases.
Stereoselective access to heteroarylmethylene-substituted pyrrolidines: fully organocatalytic Mannich–hydroamination reactions
作者:Alexandre Jean、Jérôme Blanchet、Jacques Rouden、Jacques Maddaluno、Michaël De Paolis
DOI:10.1039/c2cc38954a
日期:——
A one-pot sequence of organocatalytic transformations delivers heteroarylmethylene-substituted pyrrolidines with high stereo- and enantioselectivity. A Mannich coupling of N-heteroarylalkyne aldehydes with aldimine and an original metal-free hydroamination of the resulting adducts are the key transformations of the process delivering highly functionalized molecules with high potential for synthetic applications.